Article | November 18, 2026

When Do Supplements And Food Studies Require An IND Application?

Source: BRANY

By Raffaella Hart, MS, CIP, and Linda Reuter

clinicla-trials-automation-GettyImages-2205446822

A dietary supplement or food product may already be widely available, but that does not automatically mean it can be studied without an Investigational New Drug (IND) application. The determining factor is often the study’s intent. Research evaluating normal structure or function may not require an IND, while investigating the same product for diagnosing, treating, mitigating, or preventing a disease may trigger IND requirements.

Protocol objectives and endpoints play a critical role in that determination, including secondary and exploratory endpoints that could imply a disease claim. Even enrolling participants who have a particular condition does not automatically require an IND. Instead, the intended use of the product within the study guides the regulatory assessment.

Understanding these distinctions early can help researchers select the appropriate regulatory pathway and avoid delays in IRB approval.

Access The Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.

Subscribe to Clinical Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Clinical Leader